Anales de la RANM

98 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LINFOMA DE HODGKIN Fernández-Rañada JM An RANM. 2022;139(01): 88 - 99 21. Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: Fi- nal results of the international, randomized phase III HD 16 trial by the German Hodgkin study group. J Clin Oncol 2019;37:2835-2845. 22. Borchmann P, Plütschow A, Kobe C, et al. PET- guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 Trial. Lancet Oncol 2021;22:223-234. 23. Sasse S, Bröckelmann PJ, Goergen H, et al. Long-Term follow-Up of contemporary treatment in early-stage Hodgkin Lymphoma: Update analysis of the German Hodgkin study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017;35:1999-2007. 24. Engert A, Diehl V, Franklin J. et al. Escalated- dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548-4554. 25. Engert A, Haverkamp H, Kobe C, et al. Redu- ced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomi- sed, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2012;379:1791-1799. 26. André MPE, Carde P, Viviani S, et al. Long- term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Med. 2020;9:6565-6575. 27. Straus DJ, Dlugosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1):5-year update of an interna- tional, open-label, randomised, phase 3 trial. Lancet Oncol 2021;8:410-421. 28. . Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin’s Lymphoma. N Eng J Med. 2016;374:2419-2429. 29. Casasnovas R-O, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, pha- se 3 study. Lancet Oncol 2019;20:202-215. 30. Borchmann P, Goergen H, Kobe C, et al. PET- guided treatment in patients with advanced- stage Hodgkin’s Lymphoma (HD18): final results of an open-label, international, rando- mised phase 3 trial by the German Hodgkin Study Group. Lancet Oncol 2017;390:2790- 2802. 31. Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPP escalated alone or in combination with ri- tuximab (HD18): an open-label, internatio- nal, randomised phase 3 study by the Ger- man Hodgkin’s Study Group. Lancet Oncol 2017;18:454-463. 32. Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 2018;131:1689-1697. 33. Schmitz N, Pfistner B, Sextro M, et al. Aggres- sive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet Oncol 2002;359:2065- 2071. 34. Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 2018.131;1689-1697. 35. Constans M, Sureda A, Terol MJ, et al. Auto- logous stem cell transplantation for primary refractory Hodgkin’s disease: results and cli- nical variables affecting outcome. Ann Oncol 2003.14;745-751. 36. Martinez C, Canals C, Sarina B, et al. Identifi- cation of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann On- col 2013;24:2430-2434. 37. Moskowitz C, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomi- sed, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853-1862. 38. Martínez C, Gayoso J, Canals C, et al. Post- Transplantation cyclophosphamide-based ha- ploidentical transplantation as alternative to matched sibling or Unrelated donor transplan- tation for Hodgkin lymphoma: A registry study of the lymphoma working party of the European society for Blood and Marrow Transplantation. J Clin Oncol. 2021;35:3425-3432. 39. Ahmed S, Kanakry JA, Ahn KW, et al. Lower Graft-versus-Host disease and Relapse Risk in Post-Transplant cyclophosphamide – Based haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Blood. 2019;25:1859- 1868. 40. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin Lym- phoma after failure of autologous hematopoie- tic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428-1439. 41. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in com- bination with nivolumab in patients with relap- sed or refractory Hodgkin lymphoma. Blood. 2018;131:1183-1194. 42. Chen R, Zinzani PL, Lee HJ, et al. Pembrolizu- mab in relapsed or refractory Hodgkin lympho- ma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144-1153. 43. Armand P, Chen YB, Redd RA, et al. PD-1 bloc- kade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplan- tation. Blood. 2019;134:22-29. 44. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lym- phoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:512-524.